Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia.
Mitogen
PHA
PIDTC
SCID
Severe combined immunodeficiency
T-cell lymphopenia
T-cell proliferation
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
28
12
2023
revised:
05
02
2024
accepted:
10
02
2024
medline:
18
3
2024
pubmed:
18
2
2024
entrez:
17
2
2024
Statut:
ppublish
Résumé
Severe combined immunodeficiency (SCID) is characterized by a severe deficiency in T cell numbers. We analyzed data collected (n = 307) for PHA-based T cell proliferation from the PIDTC SCID protocol 6901, using either a radioactive or flow cytometry method. In comparing the two groups, a smaller number of the patients tested by flow cytometry had <10% of the lower limit of normal proliferation as compared to the radioactive method (p = 0.02). Further, in patients with CD3+ T cell counts between 51 and 300 cells/μL, there was a higher proliferative response with the PHA flow assay compared to the
Identifiants
pubmed: 38367737
pii: S1521-6616(24)00053-6
doi: 10.1016/j.clim.2024.109942
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109942Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest RSA has been on the advisory board for Horizon Pharma (now Amgen) and Sobi in the past 2 years but is not currently serving in that capacity. RM is an employee of Pharming Healthcare Inc., Warren, NJ. JWL is an employee and shareholder of Bluebird Bio, and has been a speaker/consultant and on the advisory board for Sobi, Inc.